Figures
- Fig. 1.—
Immunohistochemistry for a) p53 and b) YB‐1 in a representative sample of nonsmall cell lung cancer patients. Arrows indicate cells a) overexpressing p53 or b) with nuclear localisation of YB‐1. Scale bars=250 µm.
- Fig. 2.—
Western blot analysis showing the specificity of the YB‐1 antiserum. Lane 1 indicates YB‐1 antiserum and lane 2 indicates YB‐1 antiserum and peptide.
- Fig. 3.—
Survival analysis for nuclear YB‐1 expression. Kaplan-Meier analysis of overall survival in the group with nuclear YB‐1 expression (- - -; n=37) and in the group without nuclear YB‐1 expression (–––; n=40, Log rank Mantel-Cox p<0.0001).
- Fig. 4.—
Combination of survival analysis of nuclear YB‐1 expression with p53 mutational status. –––: no nuclear YB‐1 or p53 expression (n=16); ═: no nuclear YB‐1 expression but p53 expression (n=24); - - -: nuclear YB‐1 expression but no p53 expression (n=20); – - – ·: nuclear YB‐1 and p53 expression (n=17).
- Fig. 5.—
Combination of survival analysis of nuclear YB‐1 expression with p53 expression status. –––: no nuclear YB‐1 expression and wildtype p53 (n=23); ═: no nuclear YB‐1 expression and mutant p53 (n=17); - - -: nuclear YB‐1 expression and wildtype p53 (n=14); – - – ·: nuclear YB‐1 expression and mutant p53 (n=23).
Tables
- Table 1
Tumour parameters
T‐stage of primary tumour T1 11 (14) T2 27 (35) T3 19 (25) T4 20 (26) Lymph node metastases N0 20 (26) N1 15 (20) N2 21 (27) N3 21 (27) Distant metastasis M0 38 (49) M1 39 (51) Tumour stage groups IA 5 (7) IB 8 (10) IIA 3 (4) IIB 7 (9) IIIA 8 (10) IIIB 7 (9) IV 39 (51) Histological classification Adenocarcinoma 26 (34) Bronchioloalveolar carcinoma 4 (5) Squamous cell carcinoma 40 (52) Large cell carcinoma 7 (9) -
Data are presented as n (%) unless otherwise stated
-
- Table 2
Survival analysis for different subgroups
Groups Median survival months Nuclear expression No nuclear expression p‐value YB‐1 5 (37) 13 (40) p<0.0001 Stages I–III group 8 (14) 17 (24) p<0.003 Stage IV group 2 (23) 6 (16) p<0.013 Therapy group 5 (29) 15 (36) p<0.005 Best supportive care 2 (8) 3 (4) ns p53wt and 5 (14) 15 (23) p53mut 3 (23) 13 (17) p<0.0001 p53pos and 3 (17) 4 (24) p53neg 8 (20) 12 (16) p<0.0001 -
Data are presented as months survival (total n)
-
p‐value derived from Log rank-Mantel-Cox-Test
-
ns: nonsignificant
-
- Table 3
Multivariate survival analysis performed by Cox regression
Parameter Relative Risk 95% CI p‐value Nuclear YB‐1 expression 2.34 1.29–4.25 0.005 T‐staging# 1.01 0.52–1.94 0.982 N‐staging¶ 1.97 1.00–3.90 0.051 M‐staging 1.85 0.98–3.50 0.057 Treatment+ 0.60 0.27–1.30 0.192 Histopathology 0.384 Adenocarcinoma 1.00 Squamous cell carcinoma 1.11 0.64–1.93 0.711 Others§ 1.84 0.76–4.47 0.180 p53 expression 1.58 0.94–2.63 0.081 p53 mutational status 1.12 0.68–1.81 0.682 -
CI: confidence interval
-
#: T‐stage 1 and 2 versus T‐stage 3 and 4
-
¶: N‐stage 0 and 1 versus N‐stage 2 and 3
-
+: best supportive care versus treatment
-
§: bronchioloalveolar carcinoma and large cell carcinoma
-
